Cytek Biosciences, Inc. announced the appointment of Todd Garland as chief commercial officer, effective immediately, reporting directly to Dr. Wenbin Jiang, Chairman and CEO of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.69 USD | -1.22% | -3.89% | -37.61% |
29/05 | Sector Update: Health Care Stocks Lean Lower Premarket Wednesday | MT |
29/05 | Cytek Biosciences Gets Approval for Clinical Use of TBNK Reagents in China | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.61% | 756M | |
+6.02% | 217B | |
+9.25% | 190B | |
+19.58% | 141B | |
+29.74% | 110B | |
+1.63% | 64.8B | |
+15.27% | 52.44B | |
+2.69% | 49.94B | |
-5.47% | 42.63B | |
+1.58% | 35.81B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Appoints Todd Garland as Chief Commercial Officer